Fresenius Medical Care AG(FMS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, organic revenue increased by 8%, reported operating income grew by 31%, and reported net income rose by 82% [7][8] - Operating income margin improved to 11.3%, aligning with the midterm target band of 10%-14% [8][10] - Earnings per share increased by 44%, reflecting both earnings strength and the impact of the accelerated share buyback program [8][13] - Net leverage improved to 2.5x, down from 3.4x at the end of 2022 [11] Business Line Data and Key Metrics Changes - Care delivery segment revenue grew nearly 2% at constant currency, with organic revenue growth reaching almost 5% [17] - Value-based care segment saw organic revenue growth of 34%, driven by contract expansion and increased member months [9][17] - Care enablement revenue grew by 2% at constant currency, supported by volume growth and positive pricing [17][18] Market Data and Key Metrics Changes - Flat same-market treatment growth was observed in the U.S., with expectations for a 2%+ recovery due to quality initiatives and the introduction of the 5008X machine [8][9] - The company anticipates continued stagnant growth in U.S. treatment volumes for 2026, with a return to growth expected once mortality levels normalize [34][37] Company Strategy and Development Direction - The company introduced the FME Reignite strategy, focusing on operational excellence, growth and innovation, and cultural enhancement [4][5] - The 5008X machine launch in the U.S. is a significant strategic initiative aimed at improving patient outcomes and operational efficiency [14][15] - The company aims for a compound annual growth rate of 3%-7% in operating income through 2028, driven by the execution of the FME Reignite strategy [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing inflationary pressures and regulatory headwinds as significant challenges for 2026 [26][29] - The company is investing EUR 100 million to EUR 150 million in the rollout of the 5008X machine and IT platform harmonization [29][31] - Management expressed confidence in returning to a 2%+ growth in same-market treatment once mortality levels normalize [34][37] Other Important Information - The company generated EUR 2.7 billion in operating cash flow in 2025, demonstrating strong cash performance [12] - A dividend of EUR 1.49 is proposed for 2025, representing a 3% increase from 2024 [13] Q&A Session Questions and Answers Question: What is the biggest drag on the business currently? - Management indicated that ongoing inflationary pressures and costs related to the launch of the new dialysis device in the U.S. are significant factors [26][27] Question: Can you estimate the cost for the large-scale 5008X launch in the U.S.? - The estimated investment for the rollout is between EUR 100 million and EUR 150 million, with about half allocated to HDF [31][32] Question: When do you expect to see a turnaround in U.S. treatment volumes? - Management projected flat growth for 2026 but expressed confidence in returning to a 2%+ growth once mortality levels normalize [34][37] Question: What is your perspective on the latest U.S. tariff changes? - Management noted that tariffs were immaterial in 2025 but expect some impact in 2026, monitoring developments closely [39][40] Question: In which locations in Germany is Fresenius Medical Care planning to invest? - The company is investing in its manufacturing plants in Schweinfurt and Sindelfingen, which are core producers of dialysis products [42][43]